Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
Rayner CR, Bulik CC, Kamal MA, Reynolds DK, Toovey S, Hammel JP, Smith PF, Bhavnani SM, Van Wart SA, Ambrose PG, Forrest A. Rayner CR, et al. Among authors: toovey s. Antimicrob Agents Chemother. 2013 Aug;57(8):3478-87. doi: 10.1128/AAC.02440-12. Epub 2013 May 13. Antimicrob Agents Chemother. 2013. PMID: 23669386 Free PMC article. Clinical Trial.
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.
Kamal MA, Smith PF, Chaiyakunapruk N, Wu DBC, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Kirkpatrick CM, Rayner CR. Kamal MA, et al. Among authors: toovey s. Br J Clin Pharmacol. 2017 Jul;83(7):1580-1594. doi: 10.1111/bcp.13229. Epub 2017 Feb 20. Br J Clin Pharmacol. 2017. PMID: 28176362 Free PMC article.
Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.
Wu DBC, Chaiyakunapruk N, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Smith PF, Kirkpatrick CM, Kamal MA, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Rayner CR. Wu DBC, et al. Among authors: toovey s. Epidemiol Infect. 2018 Mar;146(4):496-507. doi: 10.1017/S0950268818000158. Epub 2018 Feb 15. Epidemiol Infect. 2018. PMID: 29446343 Free PMC article.
Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan.
Uchimura N, Kuwahara H, Kumagai Y, Mishima K, Inoue Y, Rayner CR, Toovey S, Davies BE, Hosaka Y, Abe M, Prinssen EP. Uchimura N, et al. Among authors: toovey s. Basic Clin Pharmacol Toxicol. 2011 Oct;109(4):309-14. doi: 10.1111/j.1742-7843.2011.00726.x. Epub 2011 Jun 29. Basic Clin Pharmacol Toxicol. 2011. PMID: 21592308 Free article. Clinical Trial.
Cost-Utility Analysis of Optimal Dosing of Oseltamivir Under Pandemic Influenza Using a Novel Approach: Linking Health Economics and Transmission Dynamic Models.
Wu DB, Chaiyakunapruk N, Pratoomsoot C, Lee KK, Chong HY, Nelson RE, Smith PF, Kirkpatrick C, Kamal MA, Nieforth K, Dall G, Toovey S, Kong DC, Kamauu A, Rayner C. Wu DB, et al. Among authors: toovey s. Value Health. 2014 Nov;17(7):A807. doi: 10.1016/j.jval.2014.08.527. Epub 2014 Oct 26. Value Health. 2014. PMID: 27203045 Free article. No abstract available.
Determinants of antiviral effectiveness in influenza virus A subtype H5N1.
Chan PK, Lee N, Zaman M, Adisasmito W, Coker R, Hanshaoworakul W, Gasimov V, Oner AF, Dogan N, Tsang O, Phommasack B, Touch S, Bamgboye E, Swenson A, Toovey S, Dreyer NA. Chan PK, et al. Among authors: toovey s. J Infect Dis. 2012 Nov;206(9):1359-66. doi: 10.1093/infdis/jis509. Epub 2012 Aug 20. J Infect Dis. 2012. PMID: 22927451
91 results